血友病A伴抑制物患者中和性抗艾美赛珠单抗抗体的特征分析
该研究报道一例参加HAVEN2试验的儿童血友病A伴抑制物患者,在艾美赛珠单抗预防治疗失去疗效后,对其中和性抗艾美赛珠单抗抗体进行了特征分析。抗体高度多克隆,主要高亲和力结合艾美赛珠单抗的Fab段,少量结合Fc段;分子互作实验提示至少存在两种亲和力相似的抗体成分。研究强调虽中和抗体罕见,但对疗效不佳者需密切监测并开发简易实验室检测方法。
要点
- 艾美赛珠单抗治疗失效时需警惕中和性抗艾美赛珠单抗抗体。
- 该抗体高度多克隆,主要高亲和力结合Fab段,少量结合Fc段。
- 分子互作实验提示至少两种亲和力相似的抗体成分。
核心结论
- 中和性抗艾美赛珠单抗抗体虽罕见,但可导致治疗失效,需密切监测并开发简易检测方法。
研究设计与样本
- 病例报告:一例参加HAVEN2临床试验的儿童血友病A伴抑制物患者。
- 采用Western blot和ELISA对抗体进行特征分析,亲和纯化后测序。
- 采用表面等离子共振和生物层干涉分析抗体与全长及木瓜蛋白酶消化艾美赛珠单抗的结合亲和力。
主要发现
- 中和性抗艾美赛珠单抗抗体高度多克隆。
- 抗体主要高亲和力结合艾美赛珠单抗的Fab段,少量结合Fc段。
- 艾美赛珠单抗与纯化抗体的分子互作实验提示至少存在两种亲和力相似的抗体成分。
临床怎么用
- 对艾美赛珠单抗疗效不佳的患者应警惕中和性抗艾美赛珠单抗抗体。
- 临床需密切监测,并推动简易实验室检测方法以尽早发现此类抗体。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The genetically engineered, humanized, bispecific monoclonal antibody emicizumab (Hemlibra) that mimics the cofactor activity of activated factor VIII (FVIII) has been approved for treatment of hemophilia A patients with and without inhibitor. In the pivotal premarketing clinical trials, emicizumab prophylaxis significantly reduced bleeding rates compared with previous treatments and was well tolerated. However, a consequence of this novel therapy may be the host immune response to a foreign protein. OBJECTIVE: Characterization of the neutralizing anti-emicizumab antibody associated with the loss of treatment efficacy. PATIENT: A pediatric hemophilia A patient with inhibitor enrolled in the HAVEN2 (Study of Emicizumab Administered Subcutaneously (SC) in Pediatric Participants With Hemophilia A and Factor VIII (FVIII) Inhibitors) clinical trial. METHODS: The anti-emicizumab antibody has been characterized with Western blot and enzyme-linked immunosorbent assay (ELISA). The antibody was affinity purified and sequenced. Binding affinity to full-length and papain-digested emicizumab was analyzed using surface plasmon resonance and byo-layer interferometry. RESULTS: The neutralizing anti-emicizumab antibody was highly polyclonal with high-affinity binding mainly to the Fab portion of emicizumab with a small amount of binding to the Fc portion. Molecular interaction experiments between emicizumab and the purified antibody indicated the presence of at least two components with similar affinities. CONCLUSIONS: Although the incidence of neutralizing anti-emicizumab antibody is rare, this study highlights the importance of a close monitoring and the need of a simple laboratory assay to promptly detect these antibodies in patients with a history of poor drug efficacy.
引用
- Valsecchi C, Gobbi M, Beeg M, et al. Characterization of the neutralizing anti-emicizumab antibody in a patient with hemophilia A and inhibitor. J Thromb Haemost. 2021. PMID: 33370499. doi:10.1111/jth.15226
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。